Gland Pharma Ltd. GLAND
NSE · India · Health Technology
INR 2,874.40-25.00 (-0.86%)
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Gland Pharma posts strong Q1 FY27 results with 47% PAT surge, unveils major manufacturing agreement and strategic collaborations to drive ~20% CAGR growth.
Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.
Gland Pharma Ltd (NSE:GLAND) reports a strong Q4 with 22% revenue growth, driven by CDMO business and US market expansion.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.